INNOVIVA, INC. Deferred Tax Assets, Deferred Income
INNOVIVA, INC. (INVA) had Deferred Tax Assets, Deferred Income of $0 as of 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2018-02-23
- 2017-12-31: Deferred Tax Assets, Deferred Income $0.00.
- 2016-12-31: Deferred Tax Assets, Deferred Income $1.00M.
- 2015-12-31: Deferred Tax Assets, Deferred Income $1.00M.
- 2014-12-31: Deferred Tax Assets, Deferred Income $2.00M.
| Period end | Deferred Tax Assets, Deferred Income | Deferred Tax Assets, Deferred Income as first filed |
|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-23 | |
| 2016-12-31 | $1.00M 10-K · filed 2018-02-23 | |
| 2015-12-31 | $1.00M 10-K · filed 2017-02-28 | |
| 2014-12-31 | $2.00M 10-K · filed 2016-02-24 | |
| 2013-12-31 | $5.00M 10-K · filed 2015-02-27 | $6.00M 10-K · filed 2014-03-03 |
| 2012-12-31 | $4.00M 10-K · filed 2014-03-03 | |
| 2011-12-31 | $56.00M 10-K · filed 2013-02-26 | |
| 2010-12-31 | $63.00M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |